Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1967 1
1968 6
1970 2
1972 2
1973 3
1974 3
1978 1
1979 2
1981 2
1982 1
1983 2
1988 1
1989 1
1990 1
1991 1
1992 1
1993 2
1994 4
1995 3
1996 2
1997 11
1998 6
1999 5
2000 9
2001 5
2002 11
2003 7
2004 11
2005 7
2006 21
2007 19
2008 20
2009 20
2010 24
2011 25
2012 20
2013 18
2014 26
2015 30
2016 33
2017 30
2018 23
2019 41
2020 59
2021 52
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

519 results
Results by year
Filters applied: . Clear all
Page 1
Exploring and comparing adverse events between PARP inhibitors.
LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. LaFargue CJ, et al. Among authors: coleman rl. Lancet Oncol. 2019 Jan;20(1):e15-e28. doi: 10.1016/S1470-2045(18)30786-1. Lancet Oncol. 2019. PMID: 30614472 Free PMC article. Review.
The forefront of ovarian cancer therapy: update on PARP inhibitors.
Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, Pignata S. Mirza MR, et al. Among authors: coleman rl. Ann Oncol. 2020 Sep;31(9):1148-1159. doi: 10.1016/j.annonc.2020.06.004. Epub 2020 Jun 20. Ann Oncol. 2020. PMID: 32569725 Free article. Review.
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.
Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, Buda A, Yan X, Shuzhong Y, Chetty N, Isla D, Tamura M, Zhu T, Robledo KP, Gebski V, Asher R, Behan V, Nicklin JL, Coleman RL, Obermair A. Ramirez PT, et al. Among authors: coleman rl. N Engl J Med. 2018 Nov 15;379(20):1895-1904. doi: 10.1056/NEJMoa1806395. Epub 2018 Oct 31. N Engl J Med. 2018. PMID: 30380365 Clinical Trial.
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Coleman RL, Lorusso D, Gennigens C, González-Martín A, Randall L, Cibula D, Lund B, Woelber L, Pignata S, Forget F, Redondo A, Vindeløv SD, Chen M, Harris JR, Smith M, Nicacio LV, Teng MSL, Laenen A, Rangwala R, Manso L, Mirza M, Monk BJ, Vergote I; innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators. Coleman RL, et al. Lancet Oncol. 2021 May;22(5):609-619. doi: 10.1016/S1470-2045(21)00056-5. Epub 2021 Apr 9. Lancet Oncol. 2021. PMID: 33845034 Clinical Trial.
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Coleman RL, et al. N Engl J Med. 2019 Nov 14;381(20):1929-1939. doi: 10.1056/NEJMoa1902626. N Engl J Med. 2019. PMID: 31722153 Free PMC article. Clinical Trial.
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ. Tewari KS, et al. Among authors: coleman rl. J Clin Oncol. 2019 Sep 10;37(26):2317-2328. doi: 10.1200/JCO.19.01009. Epub 2019 Jun 19. J Clin Oncol. 2019. PMID: 31216226 Free PMC article. Clinical Trial.
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Coleman RL, et al. N Engl J Med. 2019 Dec 19;381(25):2403-2415. doi: 10.1056/NEJMoa1909707. Epub 2019 Sep 28. N Engl J Med. 2019. PMID: 31562800 Free PMC article. Clinical Trial.
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.
Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, Arkenau HT, Machiels JP, Spicer JF, Jones R, Forster MD, Cornez N, Gennigens C, Johnson ML, Thistlethwaite FC, Rangwala RA, Ghatta S, Windfeld K, Harris JR, Lassen UN, Coleman RL. Hong DS, et al. Among authors: coleman rl. Clin Cancer Res. 2020 Mar 15;26(6):1220-1228. doi: 10.1158/1078-0432.CCR-19-2962. Epub 2019 Dec 3. Clin Cancer Res. 2020. PMID: 31796521 Free article. Clinical Trial.
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Coleman RL, et al. Lancet Oncol. 2017 Jun;18(6):779-791. doi: 10.1016/S1470-2045(17)30279-6. Epub 2017 Apr 21. Lancet Oncol. 2017. PMID: 28438473 Free PMC article. Clinical Trial.
519 results